56
Participants
Start Date
March 3, 2021
Primary Completion Date
April 4, 2023
Study Completion Date
April 4, 2023
Tideglusib
Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
Placebo
Matching placebo formulation
New Zealand Clinical Research (NZCR), Auckland
The Bright Alliance, Randwick
University of Rochester Medical Center, Rochester
University of Pittsburgh Medical Center, Pittsburgh
Virginia Commonwealth University - Department of Neurology. Muscular Dystrophy Translational Research Program., Richmond
University of Iowa Hospitals and Clinics, Iowa City
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Arkansas Children's Hospital, Little Rock
University of Utah Hospital, Salt Lake City
University of California, Los Angeles (UCLA), Los Angeles
Stanford University, Palo Alto
Children's Hospital London Health Sciences Centre (LHSC), London
Children's Hospital of Eastern Ontario, Ottawa
Newcastle University, Newcastle upon Tyne
Lead Sponsor
AMO Pharma Limited
INDUSTRY